Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martín, Noelia Jáñez Martínez, Beverly Moy et al.|The Lancet Oncology|2017Cited by 594
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerX. Cynthia, Matthew J. Ellis, Ron Bose et al.|Clinical Cancer Research|2017Cited by 191